OncoSil Medical (ASX:OSL) randomized the first patient at Royal Adelaide Hospital in South Australia for the TRIPP-FFX clinical trial for pancreatic cancer treatment, marking the start of patient recruitment at the hospital, according to a Tuesday filing with the Australian bourse.
The trial aims to evaluate the safety and effectiveness of the OncoSil device in conjunction with Folfirinox chemotherapy, the filing said.
Royal Adelaide Hospital's first randomized patient has increased the global TRIPP-FFX trial enrollment to 49, according to the filing.
Shares rose nearly 17% in morning trade Tuesday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。